{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:39:19Z","timestamp":1792546759209,"version":"4.5.0"},"reference-count":78,"publisher":"Harborside Press, LLC","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:p>Mesothelioma is a rare cancer that originates from the mesothelial surfaces of the pleura and other sites, and is estimated to occur in approximately 3,500 people in the United States annually. Pleural mesothelioma is the most common type and represents approximately 85% of these cases. The NCCN Guidelines for Mesothelioma: Pleural provide recommendations for the diagnosis, evaluation, treatment, and follow-up for patients with pleural mesothelioma. These NCCN Guidelines Insights highlight significant updates to the NCCN Guidelines for Mesothelioma: Pleural, including revised guidance on disease classification and systemic therapy options.<\/jats:p>","DOI":"10.6004\/jnccn.2024.0014","type":"journal-article","created":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T19:36:02Z","timestamp":1710790562000},"page":"72-81","source":"Crossref","is-referenced-by-count":29,"title":["Mesothelioma: Pleural, Version 1.2024"],"prefix":"10.6004","volume":"22","author":[{"given":"James","family":"Stevenson","sequence":"first","affiliation":[{"name":"Case Comprehensive Cancer Center\/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Ettinger","sequence":"additional","affiliation":[{"name":"The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas E.","family":"Wood","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dara L.","family":"Aisner","sequence":"additional","affiliation":[{"name":"University of Colorado Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wallace","family":"Akerley","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute at the University of Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica R.","family":"Bauman","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit","family":"Bharat","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debora S.","family":"Bruno","sequence":"additional","affiliation":[{"name":"Case Comprehensive Cancer Center\/ University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe Y.","family":"Chang","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucian R.","family":"Chirieac","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Brigham and Women\u2019s Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm","family":"DeCamp","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aakash","family":"Desai","sequence":"additional","affiliation":[{"name":"O\u2019Neal Comprehensive Cancer Center at UAB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Dilling","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Dowell","sequence":"additional","affiliation":[{"name":"UT Southwestern Simmons Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Durm","sequence":"additional","affiliation":[{"name":"Indiana University Melvin and Bren Simon Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina C.","family":"Garassino","sequence":"additional","affiliation":[{"name":"The UChicago Medicine Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Gettinger","sequence":"additional","affiliation":[{"name":"Yale Cancer Center\/Smilow Cancer Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis E.","family":"Grotz","sequence":"additional","affiliation":[{"name":"Mayo Clinic Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Gubens","sequence":"additional","affiliation":[{"name":"UCSF Helen Diller Family Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudy P.","family":"Lackner","sequence":"additional","affiliation":[{"name":"Fred & Pamela Buffett Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lanuti","sequence":"additional","affiliation":[{"name":"Mass General Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jules","family":"Lin","sequence":"additional","affiliation":[{"name":"University of Michigan Rogel Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Billy W.","family":"Loo","sequence":"additional","affiliation":[{"name":"Stanford Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M.","family":"Lovly","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Maldonado","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erminia","family":"Massarelli","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Morgensztern","sequence":"additional","affiliation":[{"name":"Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trey C.","family":"Mullikin","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ng","sequence":"additional","affiliation":[{"name":"The University of Tennessee Health Science Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Otterson","sequence":"additional","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Owen","sequence":"additional","affiliation":[{"name":"Mayo Clinic Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandip P.","family":"Patel","sequence":"additional","affiliation":[{"name":"UC San Diego Moores Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tejas","family":"Patil","sequence":"additional","affiliation":[{"name":"University of Colorado Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricio M.","family":"Polanco","sequence":"additional","affiliation":[{"name":"UT Southwestern Simmons Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Riely","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Riess","sequence":"additional","affiliation":[{"name":"UC Davis Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa A.","family":"Shapiro","sequence":"additional","affiliation":[{"name":"The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi P.","family":"Singh","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center at the University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alda","family":"Tam","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tawee","family":"Tanvetyanon","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Yanagawa","sequence":"additional","affiliation":[{"name":"UCLA Jonsson Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen C.","family":"Yang","sequence":"additional","affiliation":[{"name":"The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Yau","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Gregory","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Hang","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","article-title":"SEER cancer statistics review (CSR) 1975\u20132015","author":"Noone AM","unstructured":"Noone AM, Howlader N, Krapcho M,  SEER cancer statistics review (CSR) 1975\u20132015. Accessed April 1, 2018. Available at: https:\/\/seer.cancer.gov\/csr\/1975_2015\/"},{"key":"B2","unstructured":"American Cancer Society. Special section: rare cancers in adults. Accessed May 1, 2023. Available at: https:\/\/tinyurl.com\/yb4joe3c"},{"key":"B3","series-title":"Crit Rev Toxicol","first-page":"576","article-title":"Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data for 1973 through 2005","volume":"39","author":"Price B","year":"2009","unstructured":"Price B, Ware A. Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data for 1973 through 2005. Crit Rev Toxicol 2009;39:576\u2013588."},{"key":"B4","series-title":"J Clin Oncol","first-page":"2081","article-title":"Malignant pleural mesothelioma","volume":"27","author":"Tsao AS","year":"2009","unstructured":"Tsao AS, Wistuba I, Roth JA,  Malignant pleural mesothelioma. J Clin Oncol 2009;27:2081\u20132090."},{"key":"B5","unstructured":"National Cancer Institute. SEER*Explorer: all cancer sites combined, recent trends in SEER age-adjusted incidence rates, 2000\u20132020. Accessed May 1, 2023. Available at: https:\/\/seer.cancer.gov\/statistics-network\/explorer\/"},{"key":"B6","series-title":"J Cancer Res Clin Oncol","first-page":"2671","article-title":"Clinicopathological characteristics and outcomes in men with mesothelioma of the tunica vaginalis testis: analysis of published case-series data","volume":"147","author":"Grogg JB","year":"2021","unstructured":"Grogg JB, Fronzaroli JN, Oliveira P,  Clinicopathological characteristics and outcomes in men with mesothelioma of the tunica vaginalis testis: analysis of published case-series data. J Cancer Res Clin Oncol 2021;147:2671\u20132679."},{"key":"B7","series-title":"Lung Cancer","first-page":"211","article-title":"Malignant peritoneal mesothelioma\u2014results from the International Expanded Access program using pemetrexed alone or in combination with a platinum agent","volume":"64","author":"Carteni G","year":"2009","unstructured":"Carteni G, Manegold C, Garcia GM,  Malignant peritoneal mesothelioma\u2014results from the International Expanded Access program using pemetrexed alone or in combination with a platinum agent. Lung Cancer 2009;64:211\u2013218."},{"key":"B8","series-title":"Cancer Treat Rev","first-page":"605","article-title":"Diffuse malignant peritoneal mesothelioma\u2014an update on treatment","volume":"38","author":"Mirarabshahii P","year":"2012","unstructured":"Mirarabshahii P, Pillai K, Chua TC,  Diffuse malignant peritoneal mesothelioma\u2014an update on treatment. Cancer Treat Rev 2012;38:605\u2013612."},{"key":"B9","series-title":"Arch Pathol Lab Med","first-page":"113","article-title":"Malignant mesothelioma of the tunica vaginalis testis: diagnostic studies and differential diagnosis","volume":"136","author":"Chekol SS","year":"2012","unstructured":"Chekol SS, Sun CC. Malignant mesothelioma of the tunica vaginalis testis: diagnostic studies and differential diagnosis. Arch Pathol Lab Med 2012;136:113\u2013117."},{"key":"B10","series-title":"MMWR Morb Mortal Wkly Rep","first-page":"214","article-title":"Malignant mesothelioma mortality\u2014United States, 1999\u20132015","volume":"66","author":"Mazurek JM","year":"2017","unstructured":"Mazurek JM, Syamlal G, Wood JM,  Malignant mesothelioma mortality\u2014United States, 1999\u20132015. MMWR Morb Mortal Wkly Rep 2017;66:214\u2013218."},{"key":"B11","series-title":"J Surg Res","first-page":"23","article-title":"Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database","volume":"196","author":"Meyerhoff RR","year":"2015","unstructured":"Meyerhoff RR, Yang CF, Speicher PJ,  Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database. J Surg Res 2015;196:23\u201332."},{"key":"B12","series-title":"Eur Respir J","first-page":"1420","article-title":"Predicting survival in malignant mesothelioma","volume":"38","author":"Musk AW","year":"2011","unstructured":"Musk AW, Olsen N, Alfonso H,  Predicting survival in malignant mesothelioma. Eur Respir J 2011;38:1420\u20131424."},{"key":"B13","series-title":"Br J Cancer","first-page":"1860","article-title":"Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales","volume":"111","author":"Linton A","year":"2014","unstructured":"Linton A, Pavlakis N, O\u2019Connell R,  Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales. Br J Cancer 2014;111:1860\u20131869."},{"key":"B14","series-title":"MMWR Morb Mortal Wkly Rep","first-page":"645","article-title":"Malignant mesothelioma mortality in women\u2014United States, 1999\u20132020","volume":"71","author":"Mazurek JM","year":"2022","unstructured":"Mazurek JM, Blackley DJ, Weissman DN. Malignant mesothelioma mortality in women\u2014United States, 1999\u20132020. MMWR Morb Mortal Wkly Rep 2022;71:645\u2013649."},{"key":"B15","series-title":"PLoS One","first-page":"e0145039","article-title":"Determinants of survival in malignant pleural mesothelioma: a Surveillance, Epidemiology, and End Results (SEER) study of 14,228 patients","volume":"10","author":"Taioli E","year":"2015","unstructured":"Taioli E, Wolf AS, Camacho-Rivera M,  Determinants of survival in malignant pleural mesothelioma: a Surveillance, Epidemiology, and End Results (SEER) study of 14,228 patients. PLoS One 2015;10:e0145039."},{"key":"B16","series-title":"J Occup Med","first-page":"718","article-title":"Latent period for malignant mesothelioma of occupational origin","volume":"34","author":"Lanphear BP","year":"1992","unstructured":"Lanphear BP, Buncher CR. Latent period for malignant mesothelioma of occupational origin. J Occup Med 1992;34:718\u2013721."},{"key":"B17","series-title":"Cancer","first-page":"2736","article-title":"Latency of asbestos disease among insulation workers in the United States and Canada","volume":"46","author":"Selikoff IJ","year":"1980","unstructured":"Selikoff IJ, Hammond EC, Seidman H. Latency of asbestos disease among insulation workers in the United States and Canada. Cancer 1980;46:2736\u20132740."},{"key":"B18","series-title":"J Thorac Oncol","first-page":"608","article-title":"The 2021 WHO Classification of Tumors of the Pleura: advances since the 2015 classification","volume":"17","author":"Sauter JL","year":"2022","unstructured":"Sauter JL, Dacic S, Galateau-Salle F,  The 2021 WHO Classification of Tumors of the Pleura: advances since the 2015 classification. J Thorac Oncol 2022;17:608\u2013622."},{"key":"B19","series-title":"J Thorac Oncol","first-page":"142","article-title":"The 2015 World Health Organization Classification of Tumors of the Pleura: advances since the 2004 classification","volume":"11","author":"Galateau-Salle F","year":"2016","unstructured":"Galateau-Salle F, Churg A, Roggli V,  The 2015 World Health Organization Classification of Tumors of the Pleura: advances since the 2004 classification. J Thorac Oncol 2016;11:142\u2013154."},{"key":"B20","series-title":"J Clin Pathol","first-page":"854","article-title":"Challenges and controversies in the diagnosis of malignant mesothelioma: part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA","volume":"66","author":"Henderson DW","year":"2013","unstructured":"Henderson DW, Reid G, Kao SC,  Challenges and controversies in the diagnosis of malignant mesothelioma: part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA. J Clin Pathol 2013;66:854\u2013861."},{"key":"B21","series-title":"Am J Clin Oncol","first-page":"30","article-title":"Trimodality treatment of malignant pleural mesothelioma: an institutional review","volume":"41","author":"Kapeles M","year":"2018","unstructured":"Kapeles M, Gensheimer MF, Mart DA,  Trimodality treatment of malignant pleural mesothelioma: an institutional review. Am J Clin Oncol 2018;41:30\u201335."},{"key":"B22","series-title":"J Clin Oncol","first-page":"3354","article-title":"Long-term survival outcomes of cancer-directed surgery for malignant pleural mesothelioma: propensity score matching analysis","volume":"35","author":"Nelson DB","year":"2017","unstructured":"Nelson DB, Rice DC, Niu J,  Long-term survival outcomes of cancer-directed surgery for malignant pleural mesothelioma: propensity score matching analysis. J Clin Oncol 2017;35:3354\u20133362."},{"key":"B23","series-title":"J Clin Oncol","first-page":"624","article-title":"Guarantee-time bias and benefits of surgery for pleural mesothelioma","volume":"36","author":"Vogl SE","year":"2018","unstructured":"Vogl SE. Guarantee-time bias and benefits of surgery for pleural mesothelioma. J Clin Oncol 2018;36:624\u2013625."},{"key":"B24","series-title":"Radiat Oncol","first-page":"267","article-title":"Long-term results in malignant pleural mesothelioma treated with neoadjuvant chemotherapy, extrapleural pneumonectomy and intensity-modulated radiotherapy","volume":"10","author":"Thieke C","year":"2015","unstructured":"Thieke C, Nicolay NH, Sterzing F,  Long-term results in malignant pleural mesothelioma treated with neoadjuvant chemotherapy, extrapleural pneumonectomy and intensity-modulated radiotherapy. Radiat Oncol 2015;10:267."},{"key":"B25","series-title":"Lung Cancer","first-page":"75","article-title":"Survival after trimodality therapy for malignant pleural mesothelioma: radical pleurectomy, chemotherapy with cisplatin\/pemetrexed and radiotherapy","volume":"71","author":"B\u00f6l\u00fckbas S","year":"2011","unstructured":"B\u00f6l\u00fckbas S, Manegold C, Eberlein M,  Survival after trimodality therapy for malignant pleural mesothelioma: radical pleurectomy, chemotherapy with cisplatin\/pemetrexed and radiotherapy. Lung Cancer 2011;71:75\u201381."},{"key":"B26","series-title":"J Clin Oncol","first-page":"1413","article-title":"Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma","volume":"27","author":"de Perrot M","year":"2009","unstructured":"de Perrot M, Feld R, Cho BC,  Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol 2009;27:1413\u20131418."},{"key":"B27","series-title":"J Clin Oncol","first-page":"3007","article-title":"Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma","volume":"27","author":"Krug LM","year":"2009","unstructured":"Krug LM, Pass HI, Rusch VW,  Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 2009;27:3007\u20133013."},{"key":"B28","series-title":"Ann Oncol","first-page":"1196","article-title":"Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma","volume":"18","author":"Weder W","year":"2007","unstructured":"Weder W, Stahel RA, Bernhard J,  Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 2007;18:1196\u20131202."},{"key":"B29","series-title":"J Thorac Cardiovasc Surg","first-page":"54","article-title":"Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients","volume":"117","author":"Sugarbaker DJ","year":"1999","unstructured":"Sugarbaker DJ, Flores RM, Jaklitsch MT,  Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999;117:54\u201363; discussion 63\u201365."},{"key":"B30","series-title":"J Thorac Cardiovasc Surg","first-page":"558","article-title":"Pleurectomy\/decortication, hyperthermic pleural lavage with povidone-iodine, prophylactic radiotherapy, and systemic chemotherapy in patients with malignant pleural mesothelioma: a 10-year experience","volume":"149","author":"Lang-Lazdunski L","year":"2015","unstructured":"Lang-Lazdunski L, Bille A, Papa S,  Pleurectomy\/decortication, hyperthermic pleural lavage with povidone-iodine, prophylactic radiotherapy, and systemic chemotherapy in patients with malignant pleural mesothelioma: a 10-year experience. J Thorac Cardiovasc Surg 2015;149:558\u2013565; discussion 565\u2013566."},{"key":"B31","series-title":"J Thorac Oncol","first-page":"1746","article-title":"Pleurectomy\/decortication, hyperthermic pleural lavage with povidone-iodine followed by adjuvant chemotherapy in patients with malignant pleural mesothelioma","volume":"6","author":"Lang-Lazdunski L","year":"2011","unstructured":"Lang-Lazdunski L, Bille A, Belcher E,  Pleurectomy\/decortication, hyperthermic pleural lavage with povidone-iodine followed by adjuvant chemotherapy in patients with malignant pleural mesothelioma. J Thorac Oncol 2011;6:1746\u20131752."},{"key":"B32","series-title":"Ann Thorac Surg","first-page":"1658","article-title":"Radical pleurectomy and intraoperative photodynamic therapy for malignant pleural mesothelioma","volume":"93","author":"Friedberg JS","year":"2012","unstructured":"Friedberg JS, Culligan MJ, Mick R,  Radical pleurectomy and intraoperative photodynamic therapy for malignant pleural mesothelioma. Ann Thorac Surg 2012;93:1658\u20131665; discussion 1665\u20131667."},{"key":"B33","series-title":"J Thorac Cardiovasc Surg","first-page":"955","article-title":"Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection","volume":"145","author":"Sugarbaker DJ","year":"2013","unstructured":"Sugarbaker DJ, Gill RR, Yeap BY,  Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection. J Thorac Cardiovasc Surg 2013;145:955\u2013963."},{"key":"B34","series-title":"Semin Oncol","first-page":"820","article-title":"Photodynamic therapy for lung cancer and malignant pleural mesothelioma","volume":"41","author":"Simone CB 2nd","year":"2014","unstructured":"Simone CB 2nd, Cengel KA. Photodynamic therapy for lung cancer and malignant pleural mesothelioma. Semin Oncol 2014;41:820\u2013830."},{"key":"B35","series-title":"Cancer Biol Ther","first-page":"425","article-title":"Extrapleural pneumonectomy, photodynamic therapy and intensity modulated radiation therapy for the treatment of malignant pleural mesothelioma","volume":"10","author":"Du KL","year":"2010","unstructured":"Du KL, Both S, Friedberg JS,  Extrapleural pneumonectomy, photodynamic therapy and intensity modulated radiation therapy for the treatment of malignant pleural mesothelioma. Cancer Biol Ther 2010;10:425\u2013429."},{"key":"B36","series-title":"Eur J Cardiothorac Surg","first-page":"801","article-title":"Cytoreductive surgery and hyperthermic intrathoracic chemotherapy perfusion for malignant pleural tumours: perioperative management and clinical experience","volume":"43","author":"Ried M","year":"2013","unstructured":"Ried M, Potzger T, Braune N,  Cytoreductive surgery and hyperthermic intrathoracic chemotherapy perfusion for malignant pleural tumours: perioperative management and clinical experience. Eur J Cardiothorac Surg 2013;43:801\u2013807."},{"key":"B37","series-title":"Chest","first-page":"480","article-title":"Cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma or pleural metastases of thymoma","volume":"121","author":"de Bree E","year":"2002","unstructured":"de Bree E, van Ruth S, Baas P,  Cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma or pleural metastases of thymoma. Chest 2002;121:480\u2013487."},{"key":"B38","series-title":"Cancer Manag Res","first-page":"51","article-title":"New and emerging therapeutic options for malignant pleural mesothelioma: review of early clinical trials","volume":"7","author":"Kotova S","year":"2015","unstructured":"Kotova S, Wong RM, Cameron RB. New and emerging therapeutic options for malignant pleural mesothelioma: review of early clinical trials. Cancer Manag Res 2015;7:51\u201363."},{"key":"B39","series-title":"Lancet","first-page":"375","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas P","year":"2021","unstructured":"Baas P, Scherpereel A, Nowak AK,  First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet 2021;397:375\u2013386."},{"key":"B40","series-title":"Ann Oncol","first-page":"488","article-title":"First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743","volume":"33","author":"Peters S","year":"2022","unstructured":"Peters S, Scherpereel A, Cornelissen R,  First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann Oncol 2022;33:488\u2013499."},{"key":"B41","series-title":"J Clin Oncol","first-page":"2636","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang NJ","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J,  Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636\u20132644."},{"key":"B42","series-title":"Clin Lung Cancer","first-page":"30","article-title":"Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study","volume":"11","author":"Katirtzoglou N","year":"2010","unstructured":"Katirtzoglou N, Gkiozos I, Makrilia N,  Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study. Clin Lung Cancer 2010;11:30\u201335."},{"key":"B43","series-title":"J Clin Oncol","first-page":"1443","article-title":"Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma","volume":"24","author":"Ceresoli GL","year":"2006","unstructured":"Ceresoli GL, Zucali PA, Favaretto AG,  Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 2006;24:1443\u20131448."},{"key":"B44","series-title":"Ann Oncol","first-page":"370","article-title":"Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM)","volume":"19","author":"Castagneto B","year":"2008","unstructured":"Castagneto B, Botta M, Aitini E,  Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol 2008;19:370\u2013373."},{"key":"B45","series-title":"J Thorac Oncol","first-page":"756","article-title":"Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemona\u00efve patients with malignant pleural mesothelioma: results of the International Expanded Access Program","volume":"3","author":"Santoro A","year":"2008","unstructured":"Santoro A, O\u2019Brien ME, Stahel RA,  Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemona\u00efve patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol 2008;3:756\u2013763."},{"key":"B46","series-title":"Lancet","first-page":"1405","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman G","year":"2016","unstructured":"Zalcman G, Mazieres J, Margery J,  Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet 2016;387:1405\u20131414."},{"key":"B47","series-title":"Br J Cancer","first-page":"552","article-title":"Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma","volume":"109","author":"Ceresoli GL","year":"2013","unstructured":"Ceresoli GL, Zucali PA, Mencoboni M,  Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma. Br J Cancer 2013;109:552\u2013558."},{"key":"B48","series-title":"J Clin Oncol","first-page":"1343","article-title":"Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Kindler HL","year":"2018","unstructured":"Kindler HL, Ismaila N, Armato SG 3rd,  Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018;36:1343\u20131373."},{"key":"B49","series-title":"Cancer Chemother Pharmacol","first-page":"975","article-title":"A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma","volume":"73","author":"Arrieta O","year":"2014","unstructured":"Arrieta O, L\u00f3pez-Mac\u00edas D, Mendoza-Garc\u00eda VO,  A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma. Cancer Chemother Pharmacol 2014;73:975\u2013982."},{"key":"B50","series-title":"Br J Cancer","first-page":"342","article-title":"Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma","volume":"86","author":"van Haarst JM","year":"2002","unstructured":"van Haarst JM, Baas P, Manegold Ch,  Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer 2002;86:342\u2013345."},{"key":"B51","series-title":"Br J Cancer","first-page":"491","article-title":"A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma","volume":"87","author":"Nowak AK","year":"2002","unstructured":"Nowak AK, Byrne MJ, Williamson R,  A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 2002;87:491\u2013496."},{"key":"B52","series-title":"J Clin Oncol","first-page":"1556","article-title":"Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma","volume":"21","author":"Scagliotti GV","year":"2003","unstructured":"Scagliotti GV, Shin DM, Kindler HL,  Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 2003;21:1556\u20131561."},{"key":"B53","series-title":"J Thorac Oncol","first-page":"764","article-title":"Single-agent pemetrexed for chemona\u00efve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program","volume":"3","author":"Taylor P","year":"2008","unstructured":"Taylor P, Castagneto B, Dark G,  Single-agent pemetrexed for chemona\u00efve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program. J Thorac Oncol 2008;3:764\u2013771."},{"key":"B54","series-title":"Lancet","first-page":"1685","article-title":"Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial","volume":"371","author":"Muers MF","year":"2008","unstructured":"Muers MF, Stephens RJ, Fisher P,  Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 2008;371:1685\u20131694."},{"key":"B55","series-title":"JAMA Oncol","first-page":"1607","article-title":"Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis","volume":"2","author":"Nishino M","year":"2016","unstructured":"Nishino M, Giobbie-Hurder A, Hatabu H,  Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol 2016;2:1607\u20131616."},{"key":"B56","series-title":"J Clin Oncol","first-page":"709","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo J","year":"2017","unstructured":"Naidoo J, Wang X, Woo KM,  Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy. J Clin Oncol 2017;35:709\u2013717."},{"key":"B57","series-title":"Curr Drug Saf","first-page":"62","article-title":"Anti PD-1 and PDL-1 immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC): a review on toxicity profile and its management","volume":"11","author":"Sgambato A","year":"2016","unstructured":"Sgambato A, Casaluce F, Sacco PC,  Anti PD-1 and PDL-1 immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC): a review on toxicity profile and its management. Curr Drug Saf 2016;11:62\u201368."},{"key":"B58","series-title":"Ther Adv Respir Dis","first-page":"275","article-title":"Malignant pleural mesothelioma: an update on diagnosis and treatment options","volume":"10","author":"Kondola S","year":"2016","unstructured":"Kondola S, Manners D, Nowak AK. Malignant pleural mesothelioma: an update on diagnosis and treatment options. Ther Adv Respir Dis 2016;10:275\u2013288."},{"key":"B59","series-title":"BMC Cancer","first-page":"857","article-title":"Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study)","volume":"15","author":"Raynaud C","year":"2015","unstructured":"Raynaud C, Greillier L, Mazieres J,  Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study). BMC Cancer 2015;15:857."},{"key":"B60","series-title":"Hematol Oncol Clin North Am","first-page":"1117","article-title":"An overview of chemotherapy for mesothelioma","volume":"19","author":"Krug LM","year":"2005","unstructured":"Krug LM. An overview of chemotherapy for mesothelioma. Hematol Oncol Clin North Am 2005;19:1117\u20131136."},{"key":"B61","series-title":"Expert Rev Respir Med","first-page":"533","article-title":"Systemic therapy options for malignant pleural mesothelioma beyond first-line therapy: a systematic review","volume":"9","author":"Abdel-Rahman O","year":"2015","unstructured":"Abdel-Rahman O, Kelany M. Systemic therapy options for malignant pleural mesothelioma beyond first-line therapy: a systematic review. Expert Rev Respir Med 2015;9:533\u2013549."},{"key":"B62","series-title":"J Natl Compr Canc Netw","first-page":"42","article-title":"Novel therapies in phase II and III trials for malignant pleural mesothelioma","volume":"10","author":"Zauderer MG","year":"2012","unstructured":"Zauderer MG, Krug LM. Novel therapies in phase II and III trials for malignant pleural mesothelioma. J Natl Compr Canc Netw 2012;10:42\u201347."},{"key":"B63","series-title":"Lancet Oncol","first-page":"e301","article-title":"Immunotherapies for non-small-cell lung cancer and mesothelioma","volume":"13","author":"Thomas A","year":"2012","unstructured":"Thomas A, Hassan R. Immunotherapies for non-small-cell lung cancer and mesothelioma. Lancet Oncol 2012;13:e301\u2013310."},{"key":"B64","series-title":"Cancer Treat Rev","first-page":"24","article-title":"Second-line treatment for malignant pleural mesothelioma","volume":"36","author":"Ceresoli GL","year":"2010","unstructured":"Ceresoli GL, Zucali PA, Gianoncelli L,  Second-line treatment for malignant pleural mesothelioma. Cancer Treat Rev 2010;36:24\u201332."},{"key":"B65","series-title":"Lancet Oncol","first-page":"1530","article-title":"Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial","volume":"22","author":"Fennell DA","year":"2021","unstructured":"Fennell DA, Ewings S, Ottensmeier C,  Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol 2021;22:1530\u20131540."},{"key":"B66","series-title":"Lancet Oncol","first-page":"239","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel A","year":"2019","unstructured":"Scherpereel A, Mazieres J, Greillier L,  Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol 2019;20:239\u2013253."},{"key":"B67","series-title":"Lancet Respir Med","first-page":"260","article-title":"Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial","volume":"7","author":"Disselhorst MJ","year":"2019","unstructured":"Disselhorst MJ, Quispel-Janssen J, Lalezari F,  Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. Lancet Respir Med 2019;7:260\u2013270."},{"key":"B68","series-title":"J Clin Oncol","article-title":"Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: results of the IFCT-1501 MAPS2 randomized phase 2 trial","volume":"35","author":"Scherpereel A","year":"2017","unstructured":"Scherpereel A, Mazieres J, Greiller L,  Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: results of the IFCT-1501 MAPS2 randomized phase 2 trial. J Clin Oncol 2017;35(Suppl):Abstract LBA8507."},{"key":"B69","series-title":"Ann Oncol","article-title":"Second or 3rd line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: updated results of the IFCT-1501 MAPS2 randomized phase 2 trial","volume":"28","author":"Zalcman G","year":"2017","unstructured":"Zalcman G, Mazieres J, Greillier L,  Second or 3rd line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: updated results of the IFCT-1501 MAPS2 randomized phase 2 trial. Ann Oncol 2017;28(Suppl 5):Abstract LBA58."},{"key":"B70","series-title":"Cancer Treat Rev","first-page":"914","article-title":"Targeting immune checkpoints: new opportunity for mesothelioma treatment?","volume":"41","author":"Marcq E","year":"2015","unstructured":"Marcq E, Pauwels P, van Meerbeeck JP,  Targeting immune checkpoints: new opportunity for mesothelioma treatment? Cancer Treat Rev 2015;41:914\u2013924."},{"key":"B71","series-title":"J Clin Oncol","first-page":"1698","article-title":"Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma","volume":"26","author":"Jassem J","year":"2008","unstructured":"Jassem J, Ramlau R, Santoro A,  Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 2008;26:1698\u20131704."},{"key":"B72","series-title":"Lung Cancer","first-page":"360","article-title":"Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey","volume":"75","author":"Zucali PA","year":"2012","unstructured":"Zucali PA, Simonelli M, Michetti G,  Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey. Lung Cancer 2012;75:360\u2013367."},{"key":"B73","series-title":"Ann Oncol","first-page":"1734","article-title":"A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial","volume":"31","author":"Popat S","year":"2020","unstructured":"Popat S, Curioni-Fontecedro A, Dafni U,  A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial. Ann Oncol 2020;31:1734\u20131745."},{"key":"B74","series-title":"Ann Oncol","first-page":"923","article-title":"Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma","volume":"16","author":"Manegold C","year":"2005","unstructured":"Manegold C, Symanowski J, Gatzemeier U,  Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol 2005;16:923\u2013927."},{"key":"B75","series-title":"Lung Cancer","first-page":"271","article-title":"Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma","volume":"84","author":"Zauderer MG","year":"2014","unstructured":"Zauderer MG, Kass SL, Woo K,  Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma. Lung Cancer 2014;84:271\u2013274."},{"key":"B76","series-title":"Cancer","first-page":"2577","article-title":"A phase II study of gemcitabine in patients with malignant pleural mesothelioma","volume":"85","author":"van Meerbeeck JP","year":"1999","unstructured":"van Meerbeeck JP, Baas P, Debruyne C,  A phase II study of gemcitabine in patients with malignant pleural mesothelioma. Cancer 1999;85:2577\u20132582."},{"key":"B77","series-title":"Lung Cancer","first-page":"94","article-title":"The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma","volume":"63","author":"Stebbing J","year":"2009","unstructured":"Stebbing J, Powles T, McPherson K,  The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer 2009;63:94\u201397."},{"key":"B78","series-title":"Lancet Oncol","first-page":"1438","article-title":"Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"22","author":"Pinto C","year":"2021","unstructured":"Pinto C, Zucali PA, Pagano M,  Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 2021;22:1438\u20131447."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/22\/2\/article-p72.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/22\/2\/article-p72.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/22\/2\/article-p72.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T19:36:02Z","timestamp":1710790562000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/22\/2\/article-p72.xml"}},"subtitle":["Featured Updates to the NCCN Guidelines"],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":78,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2024.0014","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]}}}